Evaluation of HIV prevention interventions for people who inject drugs in low-and middle-income countries-The current and future state of the art

International Journal of Drug Policy

Volumn 25, Issue 3, 2014, Pages 336-339

  Hammett, Theodore M ^a   Parsons, Danielle S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; EDITORIAL; EPIDEMIC; HARM REDUCTION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INJECTION DRUG USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS MONITORING; PROGRAM DEVELOPMENT; RESOURCE ALLOCATION; SUBSTANCE ABUSE; COMPLICATION; HIV INFECTIONS;

DEVELOPING COUNTRIES; HARM REDUCTION; HEALTH POLICY; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84902783583     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2014.01.006     Document Type: Editorial

References (48)

1. Alistar S.S., Owens D.K., Brandeau M.L. Effectiveness and cost-effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Medicine 2011, 8(3):e1000423.
2. Bastos F.I., Strathdee S.A. Evaluating effectiveness of syringe exchange programmes: Current issues and future prospects. Social Science and Medicine 2000, 51:1771-1782.
3. Bergenstrom A.M., Abdul-Quader A.S. Injection drug use, HIV, and the current response in selected low-income and middle-income countries. AIDS 2010, 24(Supp. 3):S20-S29.
4. Beyrer C., Malinowska-Sempruch K., et al. Time to act: A call for comprehensive responses to HIV in people who use drugs. The Lancet 2010, 376:551-563.
5. Booth R.E., Lehman W.E.K., Latkin C.A., Dvoryak S., Brewster J.T., Royer M.S., et al. Individual and network interventions with injection drug users in 5 Ukraine cities. American Journal of Public Health 2011, 101:336-343.
6. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. The Lancet 2010, 376:285-301.
7. Des Jarlais D.C., Pinkerton S., Hagan H., Guardino V., Feelmyer J., Cooper H., et al. 30 years on selected issues in the prevention of HIV among persons who inject drugs. Advances in Preventive Medicine 2013, Article ID 346372, 10 p. 10.1155/2013/346372.
8. Des Jarlais D.C., Semaan S. Interventions to reduce the sexual risk behaviours of injecting drug users. International Journal of Drug Policy 2005, 16S:S58-S66.
9. De Vos A., van der Helm J.J., Matser A., Prins M., Kretzschmar M.E.E. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: Evidence for harm reduction?. Addiction 2013, 10.1111/add.12125/pdf.
10. Dutta A., Wirtz A., Stanciole A., Oelrichs R., Semini I., Baral S., et al. The global epidemics among people who inject drugs 2013, World Bank, Washington, DC. 10.1596/978-0-8213-9776-3.
11. Edington A., Bayer R. When grammars collide: Harm reduction, drug detention and the challenges of international policy reform efforts in Vietnam. Global Public Health 2012, 10.1080/17441692.2012.763045.
12. Feelemyer J.P., Des Jarlais D.C., Arasteh K., Phillips B.W., Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review. Drug and Alcohol Dependence 2014, 134:251-258.
13. Go V.F., Frangakis C., Le Minh N., Latkin C.A., Ha T.V., Mo T.T., et al. Effects of an HIV peer prevention intervention on sexual and injecting risk behaviors among injecting drug users and their risk partners in Thai Nguyen, Vietnam: A randomized controlled trial. Social Science and Medicine 2013, 96:154-164. Epub 2013 July 24. 10.1016/j.socscimed.2013.07.006.
14. Hammett T.M., Bartlett N.A., Chen Y., Ngu D., Cuong D.D., Phuong N.M., et al. Law enforcement influences on HIV prevention for injection drug users: Observations from a cross-border project in China and Vietnam. International Journal of Drug Policy 2005, 16:235-245.
15. Hammett T.M., Des Jarlais D.C., Kling R., Kieu B.T., McNicholl J.M., Wasinrapee P., et al. Controlling HIV epidemics among injection drug users: Eight years of cross-border HIV prevention interventions in Vietnam and China. PLoS ONE 2012, 7(8):e43141. 10.1371/journal.pone.0043141.
16. Hammett T.M., Parsons D.S. Evaluation of HIV prevention interventions for people who inject drugs in low- and middle-income countries: Methods, gaps, challenges and opportunities. Abt Associates thought leadership paper series 2014, http://www.abtassociates.com/.
17. Hammett T.M., Wu Z., Duc T.T., Stephens D., Sullivan S., Liu W., et al. Social evils and harm reduction: The evolving policy environment for HIV prevention among injection drug users in China and Vietnam. Addiction 2008, 103:137-145.
18. Hurley S.F., Jolley D.J., Kaldor J.M. Effectiveness of needle-exchange programmes for prevention of HIV infection. The Lancet 1997, 349:1797-1800.
19. Incidence Assay Critical Path Working Group More and better information to tackle HIV epidemics: Towards improved HIV incidence assays. PLoS Medicine 2011, 8(6):e1001045. 10.1371/journal.pmed.1001045.
20. Institute of Medicine Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence 2007, National Academies Press, Washington, DC, USA.
21. Institute of Medicine, Committee on the Outcome and Impact Evaluation of Global HIV/AIDS Programmes Implemented Under the Lantos-Hyde Act of 2008 Evaluation of PEPFAR 2013, National Academies Press, Washington, DC, USA.
22. Jardine M., Crofts N., Monaghan G., Morrow M. Harm reduction and law enforcement in Vietnam: Influences on street policing. Harm Reduction Journal 2012, 9:27. http://www.harmreductionjournal.com/9/1/27.
23. Khan A.A., Khan A. Performance and coverage of HIV intervention for injection drug users: Insights from triangulation of programme, field and surveillance data from Pakistan. International Journal of Drug Policy 2011, 22:219-225.
24. Laeyendecker O., Brookmeyer R., Cousins M.M., Mullis C.E., Konikoff J., Donnell D., et al. HIV incidence determination in the United States: A multi-assay approach. Journal of Infectious Diseases 2013, 207:232-239. Epub 2012 November 5. 10.1093/infdis/jis659.
25. Li J., Gilmour S., Zhang H., Koyanagi A., Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programmes. AIDS 2012, 26:2069-2078.
26. MacDonald M., Law M., Kaldor J., Hales J., Dore G.J. Effectiveness of needle and syringe programmes for preventing HIV transmission. International Journal of Drug Policy 2003, 14:353-357.
27. Marinda E.T., Hargrove J., Preiser W., Slabbert H., van Zyl G., Levin J., et al. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2010, 53:496-499.
28. Mathers B.M., Cook C., Degenhardt L. Improving the data to strengthen the global response to HIV among people who inject drugs. International Journal of Drug Policy 2010, 21:100-102.
29. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattrick R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet 2010, 375:1014-1028. 10.1016/S0140-6736(10)60232-2.
30. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. The Lancet 2008, 372:1733-1745. 10.1016/S0140-6736(08)61311-2.
31. Meader N., Li R., Des Jarlais D.C., Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database of Systematic Reviews 2010, 20(1):CD007192. 10.1002/14651858.CD007192.pub2.
32. Metzger D., Donnell D., Jackson B., Celentano D., Aramrattana A., Shao Y., et al. One year of counseling supported buprenorphine-naloxone treatment for HIV prevention in opiate dependent injecting drug users showed efficacy in reducing opiate use and injection frequency: HPTN 058 in Thailand and China. Poster abstract THPE191 presented at XIX international AIDS conference 2012.
33. Narayanan S., Vicknasingam B., Robson N.M. The transition to harm reduction: Understanding the role of non-governmental organisations in Malaysia. International Journal of Drug Policy 2011, 22:311-317. 10.1016/j.drugpo.2011.01.002.
34. Ni M.J., Fu L.P., Chen X.L., Hu X.Y., Wheeler K. Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, People's Republic of China (2005-2010). BMC Public Health 2012, 12:572.
35. Pilcher A., Kassanjee R., Motta L., Facente S., Keating S., McKinney E., et al. A novel quantitative, multi-analyte rapid test for recent HIV infection and HIV incidence estimation. Poster abstract TUPE194 presented at XIX international AIDS conference 2012.
36. Quality Health Care Project in the Central Asian Republics Regional strategy 2011, Quality Health Care Project, Abt Associates Inc., Bethesda, MD, USA.
37. Schackman B.R. Implementation science for the prevention and treatment of HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes 2010, 55(Suppl. 1):S27-S31. 10.1097/QAI.0b013e3181f9c1da.
38. Schottenfeld R.S., Chawarski M.C., Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomised, double-blind, placebo-controlled trial. The Lancet 2008, 371:2192-2200.
39. Sharma M., Chatterjee A. Partnering with law enforcement to deliver good public health: The experience of the HIV/AIDS Asia regional programme. Harm Reduction Journal 2012, 9:24. http://www.harmreduction%20journal.com/content/9/1/24.
40. Vickerman P., Hickman M. Commentary on de Vos et al. (2013): Can ecological trends in HIV or HCV incidence be used to assess intervention impact?. Addiction 2013, 108:1082-1083.
41. Welte A., McWalter T.A., Barnighausen T. A simplified formula for inferring HIV incidence from cross-sectional surveys using a test for recent infection. AIDS Research and Human Retroviruses 2009, 25:125-126.
42. Welte A., McWalter T.A., Laeyendecker O., Hallett T.B. Using tests for recent infection to estimate incidence: Problems and prospects for HIV. European Surveillance 2010, 15:24.
43. Wodak A. Controlling HIV among injecting drug users: The current status of harm reduction. HIV/AIDS Policy and Law Review 2006, 11:77-80.
44. Wodak A. Alex Wodak defends harm reduction, under attack from the World Forum Against Drugs, letter to David Evans 2008, http://transform-drugs.blogspot.com/2008/09/alex-wodak-defends-harm-reduction-under.html Accessed 16.03.13.
45. World Health Organisation, United Nations Office on Drugs and Crime, and United Nations Joint Programme on AIDS Technical guide for countries to set targets for universal access to HIV prevention, treatment, and care for injection drug users 2009, WHO, Geneva, Switzerland.
46. World Health Organisation, United Nations Office on Drugs and Crime, and United Nations Joint Programme on AIDS Technical guide for countries to set targets for universal access to HIV prevention, treatment, and care for injecting drug users - 2012 revision 2012, WHO, Geneva, Switzerland.
47. Zamani S., Vazirian M., Nassirimanesh B., Razzaghi E.M., Ono-Kihara M., Ravari S.M., et al. Needle and syringe sharing practices among injecting drug users in Tehran: A comparison of two neighborhoods, one with and one without a needle and syringe programme. AIDS and Behaviour 2010, 14:885-890. 10.1007/s10461-008-9402-2.
48. Zhou S., Zhang K.L., Zhang L.L., Kang J.X., Zhang J.X., Lai W.H., et al. A quasi-experimental study on a community-based behaviour change programme among injecting drug users in Sichuan, China. International Journal of STD and AIDS 2009, 20:125-129. 10.1258/ijsa.2008.008145.